VEGFA and neoplasm: However, VEGF application in clinical practice requires an effective targeted delivery system because short half-life, poor biostability in vivo and several overdose-related adverse effects (such as escalated inflammation and trigger neoplasms development) significantly limit VEGF usage [68].